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Supplementary Fig. 1 Genomic analysis of 119 prospectively and retrospectively sequenced UTUC 




Supplementary Table 1 Clinico-pathological characteristics of the UTUC samples analyzed  
by RNA-seq.  
 
Characteristic Number of patients (%) 
  Number of patients 80 
  Male gender 53 (66%) 
  Race  
      Caucasian 73 (91%) 
      African-American 2 (2.5%) 
      Asian 2 (2.5%) 
      Hispanic 1 (1.5%) 
      Unknown 2 (2.5%) 
  Smoking status  
      Never 20 (25%) 
      Former 49 (61%) 
      Active 11 (14%) 
  Histology 
 
      UC, NOS 75 (94%) 
      UC with variant histology 5 (6%) 
      High grade 66 (83%) 
  Pathologic tumor stage 
 
      pTa 23 (29%) 
      pT1 14 (17%) 
      pT2 11 (14%) 
      pT3 27 (34%) 
      pT4 5 (6%) 
  Pathologic node stage 
 
      pN0 53 (66%) 
      pN1-2 15 (19%) 
      pNx 12 (15%) 
  Positive surgical margin 5 (6%) 
  Received NAC 6 (8%) 
  Received adjuvant chemotherapy 3 (4%) 




Supplementary Table 2 Propagation and preservation of PDX models of UTUC. To minimize the r isk 
of a loss of tumorigenicity with subsequent passages, multiple early-passage tumor fragments were 
frozen for future implantation. The viability of freeze-thaw has been confirmed for majority of cases 








UCC01 P6 Yes at P3 multiple passages 
UCC03 P7 Yes at P2 multiple passages 
UCC05 P6 Yes at P2 multiple passages 
UCC08 P4 Yes at P3 multiple passages 
UCC09 P5 Yes at P4 multiple passages 
UCC11 P6 NA multiple passages 
UCC14 P9 Yes at P4 multiple passages 
UCC15 P4 NA Line is lost at P4 after freeze/thaw 
UCC17 P9 Yes at P1, P2, P5 multiple passages 
UCC19 P5 Yes at P4 multiple passages 
UCC30 P7 Yes at P2 multiple passages 
UCC32 P7 Yes at P3 multiple passages 
UCC34 P3 NA multiple passages 
UCC36 P5 Yes at P3 multiple passages 
UCC40 P7 NA multiple passages 
UCC47 P6 NA multiple passages 












Line ID Origin Passage In vivo growth 
UCC03 PDX from abdominal metastasis > P15 Yes 
UCC14 PDX from primary > P15 Yes 
UCC17 Primary > P15 Yes 
UCC32 Primary > P15 No 
UCC36 Primary > P11 Yes 




Supplementary Fig. 2 In vivo tumorigenicity of PDC. Four PDC were directly generated from patient 
specimens while two PDC (UCC03, UCC14) were derived from PDX tumors at passage 3. Four of 5 
PDC tested were able to form tumors in vivo following subcutaneous injection of cells into NSG mice. 





Supplementary Table 3. Pathology review of patient-matched UTUC tumor and PDX models. Sixteen 





patient tumor matching PDX tumor 
UCC01 UC, NOS UC, NOS 
UCC03 UC, NOS UC, NOS 
UCC05 UC, NOS UC, NOS 
UCC08 UC, NOS UC, NOS 
UCC09 UC with nested and microcystic changes UC with nested and microcystic changes 
UCC11 UC with focal squamous differentiation UC with focal squamous differentiation 
UCC14 UC, NOS UC, NOS 
UCC15 
UC exhibiting a predominant nested 
pattern of growth and focal squamous 
differentiation 
UC exhibiting a predominant nested 
pattern of growth and focal squamous 
differentiation 
UCC17 UC, NOS UC, NOS 
UCC19 UC with focal squamous differentiation UC with focal squamous differentiation 
UCC30 UC, NOS UC, NOS 
UCC32 UC, NOS UC, NOS 
UCC34 UC, NOS UC with squamous differentiation 
UCC36 UC, NOS UC, NOS 
UCC40 UC, NOS UC, NOS 
UCC47 UC, NOS UC, NOS 




   
Supplementary Fig. 3 Comparative examination of extracellular matrix architecture between matched 
patient tumors, patient derived xenografts (PDX) or/and a xenografts generated from the corresponding 
patient derived cell line (PDC). a UCC36 tumors stained with Picro Sirius Red (left panel, n=1 per each 
staining) or unstained tissues were imaged using second harmonics generation with a 2 Photon 
microscope at 880nm (right panel, n=1 per each staining). Scale bar corresponds to 200 µm b 
Quantification of the area covered by collagen in Sirius Red staining. The collagen sheets of PDX and 
xenograft were similar in architecture but covered a smaller percentage area compared to the 
corresponding patient tumor. c Masson’s trichrome staining which highlights the fibrous collagenous 
tracts in blue was performed for three sets of patient tumor, matching PDX and xenografts derived from 
PDC. All three of the primary tumors and their corresponding PDX or PDC xenografts examined 
exhibited the presence of a well-defined border and presence of fibrous structures inside the tumor. 





Supplementary Fig. 4 Mutation signature decomposition analysis for the four MSI-H patient 
tumor/xenograft model pairs. MSI signatures accounting for more than 20% of the mutations identif ied 





Supplementary Fig. 5 Mutational concordance by WES of the UCC30 and UCC03 models . a  For the 
samples shown in Fig. 2d, mutations were divided into truncal mutations shared across all samples 
derived for the specified patient, private mutations unique to individual samples and branch mutations 
that were shared by some but not all samples from the specified patient. b Related to Fig. 2e. SNP 



















Supplementary Fig 6. Chemosensitivity of the MSI-H UCC36 PDX model. The PDX model was treated 
with either the combination of gemcitabine and cisplatin (gray square) or vehicle (black circle) only as 
control (p=0.383). Two-way ANOVA test (Prism) was used for statistical analysis without adjustment. 
Data are presented as mean values +/- SD. 
control (n=6) 
gemcitabine/cisplatin (n=8) 
p =0.383 
